ADAPYCIK 1621227

Adaptimmune Therapeutics PLC

EDGAR filings

Customers

1 disclosed

Suppliers

None disclosed

Largest customer

93%

GENENTECH INC · FY to 2024-12-31

Named-customer revenue

$165.6M

1 customer · FY to 2024-12-31

Latest period

Dec 31, 2024

10-K filed 2025-03-24

Band height is the estimated dollar value: the disclosed share × the discloser's revenue for that period (latest full year where available) or federal dollars obligated. Each side is scaled on its own; dashed outlines are named without a figure. Click a band to open its source.

Customers 1

Companies ADAPY discloses as major customers, as a share of ADAPY revenue. 1 active, 0 lapsed.

Company	% of ADAPY revenue	Est. revenue	Period	Trend	Status	Source
GENENTECH INC GENENTECH INC	93%	$165.6M	FY 2024-12-31	+67.0pp	Active	10-K 2025-03-24
During the year ended December 31, 2024, 0%, 93% and 7% of the Company’s revenues were generated from Galapagos, Genentech and GSK, respectively. 10-K filed 2025-03-24 Period FY 2024-01-01 to 2024-12-31 (93%)Accession 0001558370-25-003544 During the year ended December 31, 2023, 73%, 26% and 1% of the Company’s revenues were generated from Astellas, Genentech and GSK, respectively. 10-K filed 2024-03-06 Period FY 2023-01-01 to 2023-12-31 (26%)Accession 0001558370-24-002537 During the year ended December 31, 2022, 21%, 50% and 29% of the Company’s revenues were generated from Astellas, Genentech and GSK, respectively. 10-K filed 2023-03-06 Period FY 2022-01-01 to 2022-12-31 (50%)Accession 0001558370-23-002907

Alerts are coming

Get an email when ADAPY's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.